Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

Affiliation auteurs!!!! Error affiliation !!!!
TitreInhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA
Type de publicationJournal Article
Year of Publication2016
AuteursHouot R., Soussain C., Tilly H., Haioun C., Thieblemont C., Casasnovas O., Bouabdallah K., Morschhauser F., Le Gouill S., Salles G.A, Hoang-Xuan K., Choquet S., Marchand T., Laurent C., Pangault C., Lamy T.
JournalANNALS OF ONCOLOGY
Volume27
Pagination1349-1350
Date PublishedJUL
Type of ArticleLetter
ISSN0923-7534
Résumé

We report the results of the first prospective clinical trial testing a Hh inhibitor (Vismodegib) in patients with lymphoma or CLL. Despite frequent Hh pathway activation and good bioavailability, treatment with vismodegib did not show significant clinical efficacy in patients with lymphoma nor CLL.
DOI10.1093/annonc/mdw138